As part of a revised plan "intended to accelerate the development and minimize the development costs" for its lead therapeutic asset, AnGes MG Inc. has ended a large international Phase III program for Collategene (beperminogene perplasmid, AMG0001).
In what the Japanese venture's president and CEO Ei Yamada said was "a difficult but necessary decision," the move was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?